BIOPHARMA CREDIT PLC

Declaration of Voting Results & Voting Rights Announcements • Jun 19, 2019

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 8204C

BioPharma Credit PLC

19 June 2019

BIOPHARMA CREDIT PLC

(THE "COMPANY")

RESULT OF ANNUAL GENERAL MEETING

The Company is pleased to announce that, at the Annual General Meeting held today, all resolutions were passed on a show of hands.

The proxy votes received in relation to these resolutions were as follows:

Resolutions	Votes For	%	Votes Against	%	Votes at Chairman's Discretion	Votes Withheld
1: To receive and accept the annual report and financial statements	895,570,264	100	0	0	0	0
2: To approve the Directors' Remuneration Report	895,570,264	100	0	0	0	0
3: To re-elect Jeremy Sillem as a Director	895,570,264	100	0	0	0	0
4: To re-elect Colin Bond as a Director	895,570,264	100	0	0	0	0
5: To re-elect Duncan Budge as a Director	895,570,264	100	0	0	0	0
6: To re-elect Harry Hyman as a Director	866,249,863	96.73	29,320,401	3.27	0	0
7: To elect Stephanie Léouzon as a Director	895,570,264	100	0	0	0	0
8: To re-appoint Pricewaterhouse Coopers LLP as Auditor to the Company	895,570,264	100	0	0	0	0
9: To authorise the Directors to determine the remuneration of the Auditor	895,570,264	100	0	0	0	0
10: To approve the Company's dividend payment policy	895,570,264	100	0	0	0	0
11: To authorise the Company to make market purchases of ordinary shares	790,025,298	89.98	88,000,000	10.02	0	17,544,966
12: To authorise the Company to hold general meetings on 14 clear days' notice	895,570,264	100	0	0	0	0

A copy of resolutions 11 and 12 has been submitted to the National Storage Mechanism and will shortly be available for inspection at www.morningstar.co.uk/uk/NSM

19 June 2019

Enquiries:

Buchanan

David Rydell / Mark Court / Jamie Hooper / Henry Wilson

+44 (0) 20 7466 5000

Biopharmacredit@buchanan.uk.com

Notes to Editors:

BioPharma Credit PLC is London's only listed specialist debt investor to the life sciences industry and joined the LSE on 27 March 2017. The Company seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. The Company seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products.

LEI: 213800AV55PYXAS7SY24

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

RAGSFFFWUFUSEFM